Proteinuria. Persistent proteinuria, unspecified
Conditions
Interventions
Intervention group: All non-diabetic proteinuria patients aged 5 to 17 years are first given half a tablet of empagliflozin 10 mg (Gloripa manufactured by Abidi company) for 3 months, and if they tole
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
5 Years to 17 Years
Inclusion criteria
Inclusion criteria: Age between 5 to 17 years old Suffering from non-diabetic proteinuria according to the diagnosis of a nephrologist Receiving a clinically appropriate dose of ACEIs or ARBs unless treatment is not tolerated or indicated GFR more than 60ml/min
Exclusion criteria
Exclusion criteria: Moderate to severe liver failure Having type 1and 2 diabetes Sensitivity to any of the components of the drugs used Hypotension Receiving immunosuppressants in the last 6 months Having Polycystic kidney disease Poor patient compliance during medication visits Kidney transplant Concurrent administration of ACEIs or ARBs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in body measurement. Timepoint: baseline to 24 weeks. Method of measurement: scales.;Change in blood pressure. Timepoint: baseline to 24 weeks. Method of measurement: Pressure gauge device.;Change in eGFR. Timepoint: baseline to 24 weeks. Method of measurement: schwartz method.;Change in glycemic control. Timepoint: baseline to 24 weeks. Method of measurement: blood draw from vein.;Time to the first occurrence of urinary infection. Timepoint: baseline to 24 weeks. Method of measurement: urine analysis.;Time to first occurrence of AKI. Timepoint: baseline to 24 weeks. Method of measurement: SCr. | — |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline in proteinuria. Timepoint: Baseline to ?? weeks. Method of measurement: Urin analysis. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammadreza Maghamipour
Iran University of Medical Sciences
Outcome results
None listed